Laurel Wealth Advisors (North Carolina)’s Rigel Pharmaceuticals RIGL Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-150	Closed	-$6.42K	–	534
2025 Q4	$6.42K	Buy	+150	New	+$5.65K	﹤0.01%	516
2025 Q2	–	Sell	-150	Closed	-$2.7K	–	558
2025 Q1	$2.7K	Hold	150	–	–	﹤0.01%	585
2024 Q4	$2.52K	Hold	150	–	–	﹤0.01%	610
2024 Q3	$2.43K	Hold	150	–	–	﹤0.01%	572
2024 Q2	$1.23K	Hold	150	–	–	﹤0.01%	576
2024 Q1	$2.22K	Hold	150	–	–	﹤0.01%	541
2023 Q4	$2.17K	Hold	150	–	–	﹤0.01%	507
2023 Q3	$1.62K	Hold	150	–	–	﹤0.01%	518
2023 Q2	$1.94K	Hold	150	–	–	﹤0.01%	518
2023 Q1	$1.98K	Hold	150	–	–	﹤0.01%	515
2022 Q4	$2.25K	Hold	150	–	–	﹤0.01%	480
2022 Q3	$2K	Hold	150	–	–	﹤0.01%	490
2022 Q2	$2K	Hold	150	–	–	﹤0.01%	546
2022 Q1	$4K	Hold	150	–	–	﹤0.01%	514
2021 Q4	$4K	Hold	150	–	–	﹤0.01%	516
2021 Q3	$5K	Hold	150	–	–	﹤0.01%	489
2021 Q2	$7K	Hold	150	–	–	﹤0.01%	502
2021 Q1	$5K	Hold	150	–	–	﹤0.01%	507
2020 Q4	$5K	Hold	150	–	–	﹤0.01%	482
2020 Q3	$4K	Buy	+150	New	+$3.68K	﹤0.01%	444

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s RIGL Position: Q1 2026 in Review

Laurel Wealth Advisors (North Carolina) sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 150 shares — an estimated $6.42K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in RIGL in Q3 2020 and held it in 20 quarters. The position peaked at $7K in Q2 2021. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

Laurel Wealth Advisors (North Carolina) reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 150 Rigel Pharmaceuticals shares in Q1 2026, an estimated $6.42K.
Laurel Wealth Advisors (North Carolina) first reported a position in Rigel Pharmaceuticals in Q3 2020 and held it in 20 quarters.
Laurel Wealth Advisors (North Carolina)'s Rigel Pharmaceuticals position peaked at $7K in Q2 2021.
159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2026, filed 13 May 2026.